AR051512A1 - Proteina de fusion que comprende un dominio bh3 de una proteina "solo bh3" - Google Patents

Proteina de fusion que comprende un dominio bh3 de una proteina "solo bh3"

Info

Publication number
AR051512A1
AR051512A1 ARP050104939A ARP050104939A AR051512A1 AR 051512 A1 AR051512 A1 AR 051512A1 AR P050104939 A ARP050104939 A AR P050104939A AR P050104939 A ARP050104939 A AR P050104939A AR 051512 A1 AR051512 A1 AR 051512A1
Authority
AR
Argentina
Prior art keywords
protein
fusion protein
domain
solo
refers
Prior art date
Application number
ARP050104939A
Other languages
English (en)
Original Assignee
Xigen Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34927574&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR051512(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Xigen Sa filed Critical Xigen Sa
Publication of AR051512A1 publication Critical patent/AR051512A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente se refiere a una proteína de fusion que incluye como mínimo una primera porcion (I) que comprende una secuencia de tráfico y como mínimo una segunda porcion (II) que comprende una secuencia de dominio BH3 parcial o de longitud completa de una proteína ôsolo BH3ö, comprendiendo dicha proteína de fusion aminoácidos D-enantioméricos en orden retro-inverso en su porcion (I). Además, la presente se refiere a composiciones farmacéuticas que contienen dicha proteína de fusion y también al uso de dicha proteína de fusion.
ARP050104939A 2004-11-29 2005-11-25 Proteina de fusion que comprende un dominio bh3 de una proteina "solo bh3" AR051512A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04028278A EP1661912A1 (en) 2004-11-29 2004-11-29 Fusion protein comprising a BH3-domain of a BH3-only protein

Publications (1)

Publication Number Publication Date
AR051512A1 true AR051512A1 (es) 2007-01-17

Family

ID=34927574

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050104939A AR051512A1 (es) 2004-11-29 2005-11-25 Proteina de fusion que comprende un dominio bh3 de una proteina "solo bh3"

Country Status (11)

Country Link
US (1) US20080274956A1 (es)
EP (2) EP1661912A1 (es)
JP (1) JP2008521759A (es)
CN (1) CN101068832A (es)
AR (1) AR051512A1 (es)
AU (1) AU2005308990A1 (es)
BR (1) BRPI0516659A (es)
CA (1) CA2590512A1 (es)
EA (1) EA013469B1 (es)
IL (1) IL182460A0 (es)
WO (1) WO2006056370A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3031270A1 (en) 2004-03-03 2005-12-22 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
WO2007035494A2 (en) * 2005-09-16 2007-03-29 The Regents Of The University Of California Inducing expression of puma to reduce joint inflammation in the treatment of arthritis
US7582606B2 (en) * 2005-11-03 2009-09-01 The Board Of Regents Of The University Of Texas System Nadph oxidase cytosolic cofactor mutant
AU2007340162B2 (en) * 2006-12-29 2013-08-01 Revance Therapeutics, Inc. Compositions and methods of topical application and transdermal delivery of botulinum toxins stabilized with polypeptide fragments derived from HIV-TAT
CN101583274A (zh) * 2006-12-29 2009-11-18 雷文斯治疗公司 使用反向序列hiv-tat多肽的运输分子
US8785388B2 (en) * 2007-02-14 2014-07-22 Saint Louis University TAT-BH3 methods for treating arthritis
CA2694046C (en) 2007-07-26 2023-09-12 Revance Therapeutics, Inc. Cationic peptides and compositions thereof
CN101580548B (zh) * 2008-05-12 2013-06-05 中国医学科学院肿瘤研究所 抑制肿瘤生长的融合肽及其在制备抗肿瘤药物中的用途
WO2012048721A1 (en) 2010-10-14 2012-04-19 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
SG182016A1 (en) * 2010-12-14 2012-07-30 Univ Singapore Method of detecting resistance to cancer therapy
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
CA2889833A1 (en) 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and methods for safe treatment of rhinitis
US20140378528A1 (en) 2013-06-24 2014-12-25 Mirna Biomarkers of mir-34 activity
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
CA2903275A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
KR101818809B1 (ko) * 2014-07-24 2018-02-21 가톨릭대학교 산학협력단 Bad 발현 촉진제를 포함하는 엡스타인-바 바이러스 감염증 치료용 조성물
SI3377634T1 (sl) * 2015-11-19 2021-01-29 Universitaet Basel Dostava na bakterijah osnovanih proteinov
WO2023031215A2 (en) * 2021-09-02 2023-03-09 Umc Utrecht Holding B.V. Pro-apoptotic construct and use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1082310A4 (en) * 1998-04-29 2001-09-12 Univ Georgetown METHODS RELATING TO THE IDENTIFICATION AND USE OF COMPOUNDS THAT BIND TO HLA MOLECULES AS AGONISTS OR ANTAGONISTS TO HLA
EP1076711A2 (en) * 1998-05-13 2001-02-21 Incyte Pharmaceuticals, Inc. Human apoptosis associated proteins
US6673908B1 (en) * 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
EP1181306A4 (en) * 1999-05-28 2003-06-18 Apoptosis Technology Inc COMPOUNDS AND METHODS FOR REGULATING APOPTOSIS, AND METHODS OF MAKING AND SCREENING REGULATORY COMPOUNDS FOR APOPTOSIS
US20030108539A1 (en) * 2000-02-14 2003-06-12 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20030077826A1 (en) * 2001-02-02 2003-04-24 Lena Edelman Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC)
WO2003008553A2 (en) * 2001-07-17 2003-01-30 Incyte Genomics, Inc. Proteins associated with cell growth, differentiation, and death
AU2003267124A1 (en) * 2002-09-09 2004-03-29 Dana-Farber Cancer Institute, Inc. Bh3 peptides and method of use thereof
KR100685345B1 (ko) * 2004-03-27 2007-02-22 학교법인조선대학교 세포사 유도 펩타이드

Also Published As

Publication number Publication date
JP2008521759A (ja) 2008-06-26
AU2005308990A1 (en) 2006-06-01
US20080274956A1 (en) 2008-11-06
BRPI0516659A (pt) 2008-09-16
EP1817334A1 (en) 2007-08-15
CA2590512A1 (en) 2006-06-01
WO2006056370A1 (en) 2006-06-01
EP1661912A1 (en) 2006-05-31
CN101068832A (zh) 2007-11-07
EA200700973A1 (ru) 2007-12-28
EA013469B1 (ru) 2010-04-30
IL182460A0 (en) 2007-07-24

Similar Documents

Publication Publication Date Title
AR051512A1 (es) Proteina de fusion que comprende un dominio bh3 de una proteina "solo bh3"
AR038568A1 (es) Anticuerpos anti-a beta y su uso
CO5720212A1 (es) Composicion de anticuerpo her2
ES2619332T3 (es) Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
DE602006018856D1 (de) Neue nutrazeutika-zusammensetzungen
DK1791571T3 (da) Radiofluorinerede peptider
HRP20090245T1 (en) Pyy agonists and uses thereof
BR0211623A (pt) Agentes de contraste alvos multiméricos com base em peptìdeo
ECSP088962A (es) Nuevos herbicidas
DE60120806D1 (de) Server zur Bereitstellung von Navigationsinformationen
BR0313970A (pt) Composições pesticidas contendo ácidos dicarboxìlicos
ID29621A (id) ASETILENIK α-AMINO ASAM HIDROKSAMAT SULFONAMIDA BERBASIS ASAM PENGHAMBAT-PENGHAMBAT TACE
AR051765A1 (es) Compuestos de moleculas conjugadas con una actividad reforzada de absorcion de celulas
PT935609E (pt) Composicoes cristalizaveis que contem um complexo entre o dominio de protease ns3 do virus da hepatite c e ns4a cristais resultantes
DE50112802D1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
BRPI0514411B8 (pt) formulação, e, método de produzir uma formulação
WO2002030959A3 (en) Peptides derived from smac (diablo) and methods of use therefor
BRPI0606445A2 (pt) inibidores de hipersecreÇço de mucina e mÉtodos de uso
BR0308860A (pt) Fator viii modificado
DE60233558D1 (de) Aminosäurezusammensetzungen zur linderung einer fehlfunktion der leber
AR031761A1 (es) Kit de repinotano
ATE529445T1 (de) Biokinetik zur schnellen beseitigung von polypeptiden
ES2422081T3 (es) Péptido Ser-Ser-Ser-Arg y sus utilizaciones medicinales
ATE323763T1 (de) Dna & protein bindende miniatur proteine

Legal Events

Date Code Title Description
FG Grant, registration